EazeBio and UC Santa Cruz Announce Strategic Partnership to Advance Instrument-Free Diagnostic Platform

EazeBio has announced a strategic partnership with the University of California, Santa Cruz to advance and commercialize a groundbreaking instrument-free diagnostic platform.

Grass America Highlights Its Institutional Hinges Designed for Healthcare Facilities

Spaarne Gasthuis to Advance its Commitment to Patient Care with Proscia’s Software

Spaarne Gasthuis, a top clinical teaching hospital serving part of the Greater Amsterdam region, is fully digitizing its pathology practice with Concentriq® AP-Dx* from Proscia®. With this software platform, the hospital will empower its pathologists to play an even more significant role in guiding personalized treatment decisions for hundreds of thousands of patients each year.

Leading Global Cancer Center to Integrate Triomics AI Platform to Improve Clinical Trial Screening

Leading Global Cancer Center to Integrate Triomics AI Platform to Improve Clinical Trial Screening

Elixion Biotech validates its quantum-informed R&D process, proving readiness to advance precision medicines

Elixion Biotech has emerged from stealth with a breakthrough that could reshape early-stage drug discovery. In just eleven months, and without external funding, the Zurich-based therapeutics company has validated its quantum physics-informed R&D process, confirming its ability to accurately predict and identify novel drug targets. The milestone positions Elixion to advance its precision-oncology pipeline and opens the door to seed-stage investment.

Orion and Abzena Announce Exclusive Commercial License for Abzena’s Antibody

Syngene International invests in dedicated peptide laboratory and advanced automation

DNAnexus Honored with Frost & Sullivan’s 2025 Technology Innovation Leadership Award

Recognized for Global Precision Health Informatics Industry Excellence in Best Practices

Sharp Services invests $100 million in US and European facilities to increase capacity and service offerings

Ansa Biotechnologies Redefines What’s Possible in DNA Synthesis with 50 kb Sequence-Perfect Clonal Product

Ansa Biotechnologies announced the full commercial launch of its 50kb Clonal DNA product – the longest sequence-perfect synthetic DNA commercially available.

Medherant Announces Positive Results for Initial Phase 1 Clinical Trial of Testosterone Patch for Women

Oximio Welcomes Bay Area Research Logistics in Canada to the Family, Expanding Global Reach and Service Capabilities

Oximio, a global leader in supply chain solutions for the clinical research industry, is delighted to welcome Bay Area Research Logistics (BARL), Canada to the Oximio family with the agreement signed on 17th October 2025, a strategic move that strengthens Oximio’s global footprint and enhances its capabilities across the globe.

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics has initiated its Phase 2a PreciSION CF trial evaluating SION-719, the first NBD1 stabilizer, in combination with Trikafta in people with cystic fibrosis. The study marks the first time an NBD1 stabilizer has been tested alongside the current standard of care, representing a key step toward validating NBD1 as a novel, synergistic mechanism to further improve CFTR function.

KLAS Emerging Solutions Report: Ambience Healthcare Ranked #1 in Improving Clinician Experience, Top 3 in Both Improving Patient Experience and Improving Outcomes

Pillar VC, ARIA, and DSIT Announce Inaugural Encode: AI for Science Fellows

18 Encode AI fellows will be embedded into cutting-edge scientific labs across the UK

Biopharma PEG Expands Monodispersed Azide-PEG Portfolio to Advance Bioconjugation and Drug Delivery Research

Biopharma PEG Scientific Inc. has expanded its portfolio of monodispersed azide-PEG derivatives to support bioconjugation, ADC linker development, and nanoparticle surface modification. The company now offers GMP-standard manufacturing from milligram to 100-kilogram scale, ensuring consistency and scalability for research and preclinical use.

Enamine contributes to the discovery of promising broad-spectrum coronavirus antiviral

Open-science research initiative, COVID Moonshot and the AI-driven Structure-enabled Antiviral Platform (ASAP) consortium, delivered a promising pre-clinical candidate 2,000 new compounds generated for the programme are now available from Enamine’s catalogue

KLIFO Receives Regulatory Approval for New State-of-the-Art Clinical Trial Supply Facility in Copenhagen

FDB Announces First MCP Server for AI Clinical Decision Support and Other Medication Workflow Automation

FDB Announces First MCP Server for AI Clinical Decision Support and Other Medication Workflow Automation

DPYD Safety Update: Reducing the Risk of Critical or Fatal Chemotherapy Side Effects